Aileron Therapeutics Inc.

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Its lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. It reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.